Aclarion, Inc. (ACON)

Aclarion is a medical device software company focused on treating chronic low back pain through proprietary imaging analysis. The company was founded as Nocimed in 2008 and is headquartered in Broomfield, Colorado, with stock and warrants trading on the NASDAQ.

The core product is Nociscan, a cloud-based platform that combines magnetic resonance spectroscopy (MRS) with proprietary signal-processing algorithms to analyze the chemical composition of intervertebral discs. Rather than developing hardware, Aclarion leverages existing MRI machines that clinicians already own, adding a custom software protocol and data analytics layer. The technology aims to solve a longstanding surgical challenge: identifying which painful discs in the lumbar spine will respond to surgical intervention, and which should be left alone.

According to company materials, patients treated only on Nociscan-positive discs show a 97 percent surgical success rate. This potential precision could reshape how spine surgeons approach disc-related pain, moving from anatomical guessing toward measurable biomarker guidance.

Patients treated only on Nociscan-positive discs show a 97 percent surgical success rate.

The company remains in clinical validation. Its pivotal trial, called CLARITY, is enrolling 300 patients across multiple U.S. medical centers to formally establish Nociscan’s role in improving surgical decision-making. Trial success is the inflection point—without it, there is no clear path to meaningful clinical adoption or insurance reimbursement. The company has operated with minimal revenue and significant operating losses, constrained by cash runway and facing repeated Nasdaq compliance challenges. Share dilution has been substantial through successive financing rounds.

The risk profile is extreme: clinical trials fail, reimbursement may not materialize even if evidence is positive, and the spine imaging market includes large, well-capitalized incumbents. The upside case rests entirely on CLARITY validation and subsequent commercialization. For most investors, Aclarion remains a speculative bet on niche medical innovation without the financial cushion or operating history that typically precedes mainstream adoption.